Shots:

• Cellesce & Hubrecht Organoid Technology (HUB) enters into an agreement for the expansion of breast organoids utilizing bioprocessing technology and HUB’s Organoid Technology at large scale
• The focus of the agreement is to develop genetically and phenotypically stable breast cancer organoids which retains the characteristics of tumors for drug discovery programmes
• HUB’s Organoid Technology is a drug-screening technology based on LGR5+ intestinal stem cells forming polarized epithelium for pre-clinical drug discovery and validation enabling generation of in-vitro models

Click  here Ref: Cellesce | Image: Twitter